MBX-102/JNJ-39659100 (formerly known as metaglidasen) addresses insulin resistance, the underlying cause of type 2 diabetes, by modulating genes responsible for insulin sensitization. The currently marketed insulin sensitizers from the thiazolidinedione, or TZD, class carry black box warnings of increased risk of congestive heart failure due to edema and cause significant weight gain, which compromises patient compliance. |